



ASX ANNOUNCEMENT

Starpharma recognised for outstanding year with Janssen 2012 Company of the Year Award

Melbourne, Australia; Thursday 1 November 2012: Starpharma Holdings Ltd (ASX:SPL;OTCQX:SPHRY) was last night named the industry's 2012 Australian Company of the Year.

The Janssen 2012 Industry Excellence Awards were announced in Melbourne at Australia's largest industry conference AusBiotech 2012, where Starpharma was awarded the top honour.

"This has been a break-out year for the company and to receive this acknowledgement from our industry peers is truly gratifying," said Starpharma Chief Executive Officer Dr Jackie Fairley.

The *Janssen 2012 Industry Excellence Awards - Company of the Year* award - recognises a biotechnology or life sciences company that has demonstrated a significant achievement or achievements during the year with reference to commercial deals, advancement of product pipeline, intellectual property, company strategy or revenue.

Janssen-Cilag Managing Director, Chris Hourigan, said at the Award ceremony: "Janssen is delighted to sponsor the Industry Excellence Awards. Australia is a recognised global hub of innovation and we are constantly impressed by the high calibre of science, spirit of collaboration and commercial acumen demonstrated by Australian biotechnology companies and researchers and, in particular, the winners of this year's awards."

Starpharma's major achievements for the year have included:

- The completion of two concurrent Phase 3 clinical trials of VivaGel[®] as a treatment for bacterial vaginosis (BV). Results from the trials involving 500 BV sufferers are expected by early December.
- A Special Protocol Assessment (SPA) agreement with the US FDA which is a pre-agreement outlining the optimal make-up of a Phase 3 clinical trial of VivaGel[®] for the treatment of BV.
- A Phase 2 clinical trial of VivaGel[®] used as a preventive against BV recurrence also well advanced with results expected next year.
- A deal that will see Starpharma's dendrimer technology used to develop innovative crop protection formulations for Nufarm's product portfolio.
- A deal allowing global pharmaceutical giant AstraZeneca to test whether Starpharma dendrimer molecules could enhance the effectiveness of existing cancer drugs.
- Improved efficacy and more recently, significant tumour-targeting results with Starpharma's proprietary dendrimer-docetaxel formulation.
- A new dendrimer-glyphosate formulation which demonstrated improved efficacy and rain-fastness.

"I would like to acknowledge the dedication of all Starpharma staff and thank them for their contribution towards achievement of this Company of the Year Award. I would also like to thank AusBiotech and Janssen for the Award which recognizes the sustained and company-wide effort that was needed to drive this progress. We are proud recipients," concluded Dr Fairley.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma recently announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies resulting in levels of the cancer drug in tumour tissue more than 40 times greater than seen with the convention formulation. The company is also exploring dendrimer opportunities in agrochemicals in a series of industry partnerships with leading industry players including Nufarm (ASX:NUF) as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Haley Price

Mob: +61 423 139 163

hprice@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
+61 3 8532 2704

Ben Rogers, Company Secretary

ben.rogers@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected

clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.